US biotech Global Blood Therapeutics is pretty confident that it will have important regulatory news on its sickle cell disease (SCD) candidate voxelotor by Christmas.
The positive top-line data from Part A of its Phase III HOPE study suggest there is good reason for the company’s confidence.
On the primary endpoint of the proportion of patients with greater than 1 g/dL increase in hemoglobin versus baseline, a statistically-significant increase was demonstrated with voxelotor at both the 1,500mg and 900mg doses after 12 weeks of treatment versus placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze